PEG-MGF: Molecular Structure

Molecular Structure Overview#

PEG-MGF is a conjugate molecule consisting of two chemically distinct components: the native MGF (Mechano Growth Factor) E-domain peptide and a covalently attached polyethylene glycol (PEG) polymer chain. The peptide component has a molecular formula of C121H200N42O39 with a molecular weight of 2867.15 Daltons. The PEG component adds variable molecular weight depending on the polymer length, with commonly used PEG chains ranging from 2,000 to 5,000 Daltons.

The total molecular weight of PEG-MGF ranges from approximately 5,000 to 8,000 Daltons depending on the specific PEG moiety used. This is considerably larger than native MGF and significantly changes the compound's pharmacokinetic and physicochemical properties while preserving the core biological peptide sequence.

The MGF Peptide Component#

Amino Acid Sequence#

The peptide component of PEG-MGF is identical to native MGF. In single-letter code: YQPPSTNKNTKSQRRKGSTFEEHK

In three-letter code: H-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys-OH

This 24-amino acid sequence corresponds to the unique C-terminal E-domain of the human IGF-1Ec splice variant. It arises from a 49-base pair insert in exon 5 of the IGF-1 gene that causes a reading frame shift, producing a peptide sequence not found in other IGF-1 isoforms.

Key Structural Features#

The MGF peptide component retains all structural characteristics of native MGF:

• High basicity: Four lysine (K) and two arginine (R) residues give the peptide a strong net positive charge at physiological pH, with an estimated isoelectric point of approximately 10.5
• Proline-rich N-terminus: The Pro-Pro motif at positions 3-4 introduces a rigid kink in the peptide backbone that may be important for biological activity
• No disulfide bonds: The absence of cysteine residues means the peptide remains in a linear, flexible conformation
• Aromatic residues: Tyrosine (position 1), phenylalanine (position 20), and histidine (position 23) provide potential sites for receptor interactions

The PEG Component#

Polyethylene Glycol Chemistry#

PEG is a synthetic, biocompatible, water-soluble polymer with the general repeating structure: HO-(CH2-CH2-O)n-H, where n determines the molecular weight. PEG is one of the most extensively used polymers in pharmaceutical modification, with a long safety record in FDA-approved products.

Key properties of PEG relevant to PEG-MGF:

• Water solubility: Each ethylene oxide unit coordinates approximately 2-3 water molecules, creating a hydration shell that increases the apparent molecular size
• Biocompatibility: PEG is generally non-toxic, non-immunogenic, and non-antigenic at molecular weights used for peptide conjugation
• Chemical inertness: PEG itself has no biological activity and serves purely as a pharmacokinetic modifier
• Flexibility: The PEG chain is highly flexible, creating a large hydrodynamic radius relative to its molecular weight

PEGylation Sites on MGF#

The MGF peptide contains several potential sites for PEG conjugation through amine-reactive chemistry:

The specific PEGylation site used in commercially available PEG-MGF preparations is not consistently documented. The site of PEG attachment can significantly influence biological activity, as PEG positioned near a receptor-binding region may sterically hinder receptor engagement.

PEGylation Types#

Several PEGylation strategies could be applied to MGF:

• Random PEGylation: PEG is attached to whichever amine group reacts first, producing a heterogeneous mixture of positional isomers
• Site-specific PEGylation: Chemical strategies are used to preferentially modify a single site (typically the N-terminus at lower pH, since alpha-amino groups have lower pKa than epsilon-amino groups)
• Branched PEGylation: A Y-shaped or multi-arm PEG provides greater steric shielding than a linear PEG of equivalent total molecular weight

Effects of PEGylation on Properties#

Pharmacokinetic Properties#

Absorption#

Following subcutaneous injection, PEG-MGF is absorbed into the systemic circulation over a period of minutes to hours, with the absorption rate influenced by the size of the PEG moiety. Larger PEG chains slow absorption from the injection site but also extend the duration of circulating peptide concentrations.

Distribution#

Unlike native MGF, which is confined to the injection site and immediate vicinity before degradation, PEG-MGF achieves systemic distribution. The increased hydrodynamic radius (due to PEG's water of hydration shell) limits distribution to tissues with tight endothelial barriers but allows access to well-perfused tissues throughout the body.

Metabolism#

PEG-MGF is metabolized more slowly than native MGF. The PEG moiety sterically shields the peptide backbone from proteolytic enzymes, reducing the rate of enzymatic degradation. The PEG component itself is not metabolized and is cleared intact, primarily through renal excretion.

Elimination#

The elimination half-life of PEG-MGF is estimated at several hours, compared to approximately 5-7 minutes for native MGF. This estimate is based on PEGylation pharmacology principles rather than empirical pharmacokinetic studies specific to PEG-MGF.

Physical and Chemical Properties#

Analytical Characterization#

PEG-MGF requires specialized analytical methods due to the heterogeneity introduced by the PEG component:

• MALDI-TOF mass spectrometry: Determines total molecular weight distribution and confirms PEGylation
• Reverse-phase HPLC: Separates PEGylated from non-PEGylated peptide and assesses purity
• Size exclusion chromatography: Confirms increased hydrodynamic radius
• SDS-PAGE: Visualizes molecular weight shift from PEGylation
• Barium iodide staining: Specific detection of PEG polymer component
• Amino acid analysis: Confirms peptide sequence integrity after PEGylation

Comparison with Related Compounds#

Related Reading#

• PEG-MGF overview and research guide
• Peptides similar to PEG-MGF
• PEG-MGF research evidence